Effets indésirables cardiaques des chimiothérapies

摘要: The spectrum of chemotherapy's cardiac side effect chemotherapy has expanded with the new combinations cytotoxic and targeted therapies over past 10 years. Moreover, cancer therapy administrated to "new" populations, especially elderly patients or cardiovascular disease and/or coronary artery history, increased considerably. According American College Cardiology Heart Association (ACC/AHA), receiving can be considered in A group heart failure. Many adverse effects appear suspend treatment purchase, leading an alteration quality life, increasing mortality risks. most clinically evident cardiotoxicity best known is anthracyclines effect. Other are associated a significant risk complications include alkylating agents such as 5-fluorouracil paclitaxel. Cardiovascular use tyrosine kinase inhibitors: trastuzumab, bevacizumab. At same time, drugs used hematological malignancies, acid all-trans-retinoic arsenic trioxide cardiotoxics. serious congestive failure, mainly due anthracyclines, cyclophosphamide usually at high doses. Myocardial ischemia caused by interferon antimetabolites. may occur hypotension, hypertension, arrhythmias conduction disturbances, pericarditis, thromboembolic complications.